2014, ISBN 9783161532078, vii, 157 pages
Book
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4292 - 4292
Background: Novel targeted treatment options with fixed or minimal residual disease (MRD) guided duration are warranted for patients with R/R CLL....
Journal Article
Journal of Neuroimmunology, ISSN 0165-5728, 2008, Volume 200, Issue 1, pp. 100 - 110
Abstract Monocyte infiltration is an important pathogenic event in human immunodeficiency virus type one (HIV-1) associated dementia (HAD). CXCL8 (Interleukin...
Neurology | Allergy and Immunology | Inflammation | CXCL8 | Astrocyte | HIV-1 associated dementia | Macrophage | HUMAN MICROGLIA | NERVOUS-SYSTEM | MESSENGER-RNA EXPRESSION | MULTINUCLEATED GIANT-CELLS | NECROSIS-FACTOR-ALPHA | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | NEUROSCIENCES | BRAIN-TISSUE | AIDS DEMENTIA COMPLEX | GENE-EXPRESSION | HIV-1 Associated Dementia
Neurology | Allergy and Immunology | Inflammation | CXCL8 | Astrocyte | HIV-1 associated dementia | Macrophage | HUMAN MICROGLIA | NERVOUS-SYSTEM | MESSENGER-RNA EXPRESSION | MULTINUCLEATED GIANT-CELLS | NECROSIS-FACTOR-ALPHA | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | NEUROSCIENCES | BRAIN-TISSUE | AIDS DEMENTIA COMPLEX | GENE-EXPRESSION | HIV-1 Associated Dementia
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article